Tower Research Capital (TRC)’s Telesis Bio, Inc. Common Stock TBIO Stock Holding History

Tower Research Capital (TRC)’s Portfolio TBIO Stock Details TBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-173	Closed	-$1.37K	–	6088
2024 Q1	$1.37K	Buy	173 +172	+17,200%	+$1.29K	﹤0.01%	5274
2023 Q4	$9	Buy	+1	New	+$11	﹤0.01%	5852
2023 Q3	–	Sell	-53	Closed	-$1.51K	–	6335
2023 Q2	$1.51K	Sell	53 -167	-76%	-$6.67K	﹤0.01%	5364
2023 Q1	$12K	Sell	220 -277	-56%	-$9.81K	﹤0.01%	4147
2022 Q4	$11K	Buy	497 +157	+46%	+$4.27K	﹤0.01%	3901
2022 Q3	$10K	Sell	340 -74	-18%	-$2.6K	﹤0.01%	4591
2022 Q2	$13K	Buy	414 +299	+260%	+$20.6K	﹤0.01%	4239
2022 Q1	$11K	Sell	115 -29	-20%	-$4.4K	﹤0.01%	4229
2021 Q4	$28K	Buy	144 +95	+194%	+$14.8K	﹤0.01%	3318
2021 Q3	$10K	Buy	+49	New	+$12.4K	﹤0.01%	4352

Other funds holding TBIO

Northpond Ventures Bethesda, Maryland $43.7M AUM 27.27% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

DWS

Dynamic Wealth Strategies Granite Bay, California $188M AUM 18.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Tower Research Capital (TRC)'s TBIO Position: Q2 2024 in Review

Tower Research Capital (TRC) sold out of Telesis Bio, Inc. Common Stock (TBIO) in Q2 2024, closing a stake of 173 shares — an estimated $1.37K sold.

Tower Research Capital (TRC) first reported a position in TBIO in Q3 2021 and held it in 10 quarters. The position peaked at $28K in Q4 2021. 10 funds tracked by Wall St. Rank hold TBIO as of Q2 2024.

Tower Research Capital (TRC) reported no remaining Telesis Bio, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
Tower Research Capital (TRC) sold 173 Telesis Bio, Inc. Common Stock shares in Q2 2024, an estimated $1.37K.
Tower Research Capital (TRC) first reported a position in Telesis Bio, Inc. Common Stock in Q3 2021 and held it in 10 quarters.
Tower Research Capital (TRC)'s Telesis Bio, Inc. Common Stock position peaked at $28K in Q4 2021.
10 funds tracked by Wall St. Rank held Telesis Bio, Inc. Common Stock as of Q2 2024.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2024, filed 13 Aug 2024.